纖維蛋白原β(FGB)單克隆抗體
Monoclonal Antibody to Fibrinogen Beta Chain (FGB)
FG-B; Fibrinopeptide B; Fibrinogen Beta
- 編號UMAB215Hu21
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 來源單抗制備
- 宿主小鼠
- 效價(克隆號)C1
- Ig亞型 IgG2b Kappa
- 純化方式蛋白A + 蛋白G親和純化
- 標記物無標記物
- 免疫原 RPB215Hu02-纖維蛋白原β(FGB)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度1mg/mL
- 且適物種-
- 應用WB; IHC
如果抗體需用于流式細胞術，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 317 ¥ 739 ¥ 1056 ¥ 2640 ¥ 10560
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
DAB staining on IHC-P; Sample: Human Placenta Tissue; Primary Ab: 30μg/ml Mouse Anti-Human FGb Antibody Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody (Catalog: SAA544Mu19)
-
DAB staining on IHC-P;
Sample: Human Kidney Tissue;
Primary Ab: 30μg/ml Mouse Anti-Human FGb Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19) -
DAB staining on IHC-P;
Sample: Human Cerebrum Tissue;
Primary Ab: 30μg/ml Mouse Anti-Human FGb Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19) -
DAB staining on IHC-P;
Sample: Human Small intestine Tissue;
Primary Ab: 30μg/ml Mouse Anti-Human FGb Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19) -
DAB staining on IHC-P;
Sample: Human Liver Tissue;
Primary Ab: 30μg/ml Mouse Anti-Human FGb Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19)
-
Figure. Western Blot; Sample: Recombinant FGb, Human.
-
Western Blot; Sample: Lane1: Human Serum; Lane2: Human Urine; Lane3: Human Placenta lysate
Primary Ab: 3μg/ml Mouse Anti-Human FGb Antibody
Second Ab: 0.2μg/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody
(Catalog: SAA544Mu19)
-
通過ISO 9001、ISO 13485質量體系認證
特異性
該抗體是針對FGB的小鼠單克隆抗體。在免疫組織化學染色和免疫印跡實驗中能識別FGB。
用法
Western blotting: 0.01-3μg/mL
Immunohistochemistry: 5-30μg/mL
Immunocytochemistry: 5-30μg/mL
Optimal working dilutions must be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質期內，在適當?shù)臈l件下存儲，損失率低于5%。
贈品
增值服務
相關產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應用(僅供研究使用，不用于臨床診斷！) |
| URPB215Hu01 | 纖維蛋白原β(FGB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPB215Hu01 | 纖維蛋白原β(FGB)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPB215Hu03 | 纖維蛋白原β(FGB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPB215Hu02 | 纖維蛋白原β(FGB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAB215Hu03 | 纖維蛋白原β(FGB)多克隆抗體 | WB; FCM |
| UPAB215Hu01 | 纖維蛋白原β(FGB)多克隆抗體 | WB; IHC; FCM |
| UPAB215Hu02 | 纖維蛋白原β(FGB)多克隆抗體 | WB; IHC; FCM |
| ULAB215Hu71 | 纖維蛋白原β(FGB)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| ULAB215Hu81 | 纖維蛋白原β(FGB)多克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
| UMAB215Hu23 | 纖維蛋白原β(FGB)單克隆抗體 | WB; IHC |
| UMAB215Hu25 | 纖維蛋白原β(FGB)單克隆抗體 | WB |
| UMAB215Hu22 | 纖維蛋白原β(FGB)單克隆抗體 | WB; IHC |
| UMAB215Hu24 | 纖維蛋白原β(FGB)單克隆抗體 | WB; IHC |
| UMAB215Hu21 | 纖維蛋白原β(FGB)單克隆抗體 | WB; IHC |
| UFAB215Hu06 | 抗纖維蛋白原β(FGB)單克隆抗體 | Flow cytometry. |
| UFAB215Hu02 | 抗纖維蛋白原β(FGB)單克隆抗體 | FCM |
| UFAB215Hu04 | 抗纖維蛋白原β(FGB)單克隆抗體 | FCM |
| UFAB215Hu08 | 抗纖維蛋白原β(FGB)單克隆抗體 | FCM |
| ULAB215Hu72 | 纖維蛋白原β(FGB)單克隆抗體(生物素標記) | WB; IHC; ICC. |
| ULAB215Hu82 | 纖維蛋白原β(FGB)單克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
| USEB215Hu | 纖維蛋白原β(FGB)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMB215Hu | 纖維蛋白原β(FGB)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UKSB215Hu01 | 纖維蛋白原β(FGB)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| United States Patent Application | Compositions and Methods for Diagnosing Lung Cancer [y2016:0077095.html] |
| Microbial Pathogenesis | Crystal structure of GAPDH of Streptococcus agalactiae and characterization of its interaction with extracellular matrix molecules [Pubmed: 30553015] |
| GLYCOCONJUGATE JOURNAL | Nattokinase-heparin exhibits beneficial efficacy and safety—an optimal strategy for CKD patients on hemodialysis [Pubmed: 30788657] |
留言咨詢
